See more : KL Acquisition Corp (KLAQ) Income Statement Analysis – Financial Results
Complete financial analysis of Lipella Pharmaceuticals Inc. (LIPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lipella Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Takasho Co.,Ltd. (7590.T) Income Statement Analysis – Financial Results
- Paramount Cosmetics (India) Limited (PARMCOS-B.BO) Income Statement Analysis – Financial Results
- PT Ladang Baja Murni Tbk (LABA.JK) Income Statement Analysis – Financial Results
- Hiecise Precision Equipment Co.,Ltd. (300809.SZ) Income Statement Analysis – Financial Results
- Altiplano Metals Inc. (ALTPF) Income Statement Analysis – Financial Results
Lipella Pharmaceuticals Inc. (LIPO)
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 449.62K | 184.16K | 259.35K | 961.68K | 694.75K |
| Cost of Revenue | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| Gross Profit | -2.59M | -2.36M | -1.20M | -14.28K | 11.86K |
| Gross Profit Ratio | -575.87% | -1,283.43% | -461.71% | -1.48% | 1.71% |
| Research & Development | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| General & Administrative | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Other Expenses | 0.00 | -45.00 | 57.09K | 0.00 | 0.00 |
| Operating Expenses | 2.16M | 2.77M | 2.18M | 1.02M | 748.54K |
| Cost & Expenses | 5.20M | 2.77M | 2.18M | 1.02M | 748.54K |
| Interest Income | 137.84K | 1.68K | 104.00 | 3.17K | 334.00 |
| Interest Expense | 10.85K | 9.61K | 6.83K | 7.97K | 8.39K |
| Depreciation & Amortization | 1.69K | 2.59M | 1.92M | 56.86K | 53.79K |
| EBITDA | -4.61M | -2.59M | 0.00 | -53.69K | 334.00 |
| EBITDA Ratio | -1,024.52% | -1,405.37% | -716.66% | -5.58% | -7.74% |
| Operating Income | -4.75M | -2.59M | -1.92M | -56.86K | -53.79K |
| Operating Income Ratio | -1,055.55% | -1,406.26% | -738.71% | -5.91% | -7.74% |
| Total Other Income/Expenses | 126.99K | -7.98K | 50.36K | -4.79K | -8.06K |
| Income Before Tax | -4.62M | -2.60M | -1.87M | -61.66K | -61.85K |
| Income Before Tax Ratio | -1,027.31% | -1,410.59% | -719.30% | -6.41% | -8.90% |
| Income Tax Expense | 0.00 | -1.63K | 6.73K | 4.79K | -53.79K |
| Net Income | -4.62M | -2.60M | -1.87M | -66.45K | -61.85K |
| Net Income Ratio | -1,027.31% | -1,409.71% | -721.89% | -6.91% | -8.90% |
| EPS | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| EPS Diluted | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
| Weighted Avg Shares Out (Dil) | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 — Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
PITTSBURGH, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with...
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc.
Why Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?
Lipella Pharmaceuticals (NASDAQ: LIPO ) stock is flying higher on Monday after the company presented investors with an update on its Phase 2a clinical trial evaluating LP-310. This is the company's drug candidate for the treatment of Oral Lichen Planus (...
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
Top Line Data Expected Year-End 2024 Pittsburgh, July 29, 2024 — Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a...
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, PA., May 31, 2024 — Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology...
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Abstract highlighting new preclinical data from LP-50 in non-muscle invasive bladder cancer PITTSBURGH, Pa., May 29, 2024 – Lipella Pharmaceuticals Inc.
Source: https://incomestatements.info
Category: Stock Reports